Nature Communications (Sep 2021)
Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma
- Huan-Chang Liang,
- Mariantonia Costanza,
- Nicole Prutsch,
- Mark W. Zimmerman,
- Elisabeth Gurnhofer,
- Ivonne A. Montes-Mojarro,
- Brian J. Abraham,
- Nina Prokoph,
- Stefan Stoiber,
- Simone Tangermann,
- Cosimo Lobello,
- Jan Oppelt,
- Ioannis Anagnostopoulos,
- Thomas Hielscher,
- Shahid Pervez,
- Wolfram Klapper,
- Francesca Zammarchi,
- Daniel-Adriano Silva,
- K. Christopher Garcia,
- David Baker,
- Martin Janz,
- Nikolai Schleussner,
- Falko Fend,
- Šárka Pospíšilová,
- Andrea Janiková,
- Jacqueline Wallwitz,
- Dagmar Stoiber,
- Ingrid Simonitsch-Klupp,
- Lorenzo Cerroni,
- Stefano Pileri,
- Laurence de Leval,
- David Sibon,
- Virginie Fataccioli,
- Philippe Gaulard,
- Chalid Assaf,
- Fabian Knörr,
- Christine Damm-Welk,
- Wilhelm Woessmann,
- Suzanne D. Turner,
- A. Thomas Look,
- Stephan Mathas,
- Lukas Kenner,
- Olaf Merkel
Affiliations
- Huan-Chang Liang
- Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna
- Mariantonia Costanza
- European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner
- Nicole Prutsch
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Mark W. Zimmerman
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Elisabeth Gurnhofer
- Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna
- Ivonne A. Montes-Mojarro
- European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner
- Brian J. Abraham
- Department of Computational Biology, St. Jude Children’s Research Hospital
- Nina Prokoph
- European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner
- Stefan Stoiber
- Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna
- Simone Tangermann
- Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna
- Cosimo Lobello
- European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner
- Jan Oppelt
- Central European Institute of Technology (CEITEC), Masaryk University
- Ioannis Anagnostopoulos
- Institute of Pathology, University of Würzburg
- Thomas Hielscher
- German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ)
- Shahid Pervez
- Department of Pathology and Laboratory Medicine, Aga Khan University Hospital
- Wolfram Klapper
- Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein Campus Kiel
- Francesca Zammarchi
- ADC Therapeutics (UK) Limited
- Daniel-Adriano Silva
- Institute for Protein Design, University of Washington
- K. Christopher Garcia
- Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine
- David Baker
- Institute for Protein Design, University of Washington
- Martin Janz
- Group Biology of Malignant Lymphomas, Max-Delbrück-Center (MDC) for Molecular Medicine
- Nikolai Schleussner
- Group Biology of Malignant Lymphomas, Max-Delbrück-Center (MDC) for Molecular Medicine
- Falko Fend
- European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner
- Šárka Pospíšilová
- European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner
- Andrea Janiková
- European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner
- Jacqueline Wallwitz
- Department of Pharmacology, Physiology and Microbiology, Division Pharmacology, Karl Landsteiner University of Health Sciences
- Dagmar Stoiber
- Department of Pharmacology, Physiology and Microbiology, Division Pharmacology, Karl Landsteiner University of Health Sciences
- Ingrid Simonitsch-Klupp
- Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna
- Lorenzo Cerroni
- Department of Dermatology, Medical University of Graz
- Stefano Pileri
- Division of Haematopathology, European Institute of Oncology IRCCS
- Laurence de Leval
- Institute of Pathology, Lausanne University Hospital (CHUV) and Lausanne University
- David Sibon
- Hematology Department, Necker University Hospital, Assistance Publique—Hôpitaux de Paris, and Institut Necker-Enfants Malades, INSERM UMR1151 (Normal and pathological lymphoid differentiation), Université de Paris
- Virginie Fataccioli
- Department of Pathology, Henri Mondor University Hospital, AP-HP, INSERM U955, University Paris East
- Philippe Gaulard
- Department of Pathology, Henri Mondor University Hospital, AP-HP, INSERM U955, University Paris East
- Chalid Assaf
- Department of Dermatology, HELIOS Hospital Krefeld, Krefeld, Department of Dermatology and Allergy, Charité—Universitätsmedizin Berlin
- Fabian Knörr
- Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf
- Christine Damm-Welk
- European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner
- Wilhelm Woessmann
- European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner
- Suzanne D. Turner
- European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner
- A. Thomas Look
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Stephan Mathas
- European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner
- Lukas Kenner
- Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna
- Olaf Merkel
- Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna
- DOI
- https://doi.org/10.1038/s41467-021-25379-9
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
Anaplastic large cell lymphoma (ALCL) is an aggressive T-cell lymphoma often with poor prognosis. To identify genes defining ALCL cell state and dependencies, the authors here characterize ALCL-specific super-enhancers and describe the BATF3/IL-2R−module as a therapeutic opportunity for ALCL.
